1. Home
  2. Live Updates
  3. Marketing authorization applications

Live Breaking News & Updates on Marketing authorization applications

Stay informed with the latest breaking news from Marketing authorization applications on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Marketing authorization applications and stay connected to the pulse of your community

Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial...

Japan , United-states , Tennessee , France , Portugal , India , Netherlands , United-kingdom , Germany , China , Australia , Jerrell-shelton

Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion

ZUG, Switzerland--(BUSINESS WIRE)--Feb 29, 2024--

Canada , Switzerland , Dubai , Dubayy , United-arab-emirates , United-kingdom , China , Brazil , Mexico , Poland , Olympia , Sãpaulo

Nemolizumab Being Reviewed for AD, Prurigo Nodularis

For prurigo nodularis, the FDA has granted nemolizumab, a monoclonal antibody designed to inhibit interleukin-31 signaling, priority review.

Drug-administration , European-medicines-agency , Biologics-license-application , Marketing-authorization-applications , Biologic-therapy , Iologics , Prurigo-nodularis , Dermatitis , Atopic-dermatitis , Topic-eczema , Grant

Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan , Taiwan , Emil-ivanov , Christian-marcoux , Dermatol-venereol , Jessica-cohen , European-medicines-agency , European-academy-of-dermatology , Corporate-communications , Chugai-pharmaceutical-co-ltd , Drug-administration , Biologics-license-applications

CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Japan , Taiwan , Christian-marcoux , Dermatol-venereol , Jessica-cohen , Stefan-klotter , Emil-ivanov , Drug-administration , European-academy-of-dermatology , Corporate-communications , Chugai-pharmaceutical-co-ltd , European-medicines-agency

Biologics License Application for Nemolizumab Accepted by FDA for Prurigo Nodularis, Atopic Dermatitis

In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.

Baldo-scassellati-sforzolini , Drug-administration , European-medicines-agency , Biologics-license-applications , Marketing-authorization-applications , Priority-review , Breakthrough-therapy , Scassellati-sforzolini , Bla , Fda , Nemolizumab , Prurigo

Deciphering the EMA's regulatory framework: Key insights for US pharmaceutical companies

This article talks about how companies in the US can navigate the EMA's regulatory framework in order to expand and develop new pharmaceutical products.

Andrea-salazar , European-union , European-medicines-agency , Drug-administration , Company-alpha , Ds-inpharmatics , Sponsored-content , Investigational-medicinal-product-dossier , Marketing-authorization-applications , Drug-application , Content-policy , News-medical-net

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Saudi-arabia , Massachusetts , Boston , San-francisco , California , United-kingdom , Switzerland , London , City-of , Saudi , American

CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , United-kingdom , California , Boston , Massachusetts , San-francisco , Saudi-arabia , London , City-of , Switzerland , Saudi , American

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states , San-francisco , California , Saudi-arabia , Switzerland , Massachusetts , London , City-of , United-kingdom , Boston , Saudi , Kingdom-of-saudi-arabia